A David RODRIGUES (Pfizer)
Biochem Pharmacol. 2020;174:113829. Nicotinic acid transport into human liver involves organic anion transporter 2 (SLC22A7). Mathialagan S, Bi YA, Costales C, Kalgutkar AS, Rodrigues AD, Varma MVS. PubMed
J Pharmacol Exp Ther. 2020;372:308-319. Profiling of drug-metabolizing enzymes and transporters in human tissue biopsy samples: A Review of the literature. Rodrigues AD, Rowland A. V PubMed
Drug Metab Dispos. 2020;48:205-216. Induction of human intestinal and hepatic Organic Anion Transporting Polypeptides: Where is the evidence for its Relevance in Drug-Drug Interactions? Rodrigues AD, Lai Y, Shen H, Varma MVS, Rowland A, Oswald S. PubMed
Clin Pharmacol Ther. 2020;107:1128–1137.Quantitative proteomics and mechanistic modeling of transporter-mediated disposition in Non-Alcoholic Fatty Liver Disease. Vildhede A, Kimoto E, Pelis RM, Rodrigues AD, Varma MVS. PubMed
Clin Pharmacol Ther. 2020;107:1004-1013. Dose-dependent inhibition of OATP1B by Rifampicin in healthy volunteers: Comprehensive evaluation of candidate biomarkers and OATP1B probe drugs. Mori D, Kimoto E, Rago B, Kondo Y, King-Ahmad A, Ramanathan R, Wood LS, Johnson JG, Le VH, Vourvahis M, Rodrigues AD, Muto C, Furihata K, Sugiyama Y, Kusuhara H. PubMed
Chem Res Toxicol. 2020;33:223-238. Moving beyond binary predictions of human Drug-Induced Liver Injury (DILI) toward contrasting relative risk potential. Aleo MD, Shah F, Allen S, Barton HA, Costales C, Lazzaro S, Leung L, Nilson A, Obach RS, Rodrigues AD, Will Y. PubMed
Mol Pharm. 2019;16:4065-4076. Renal excretion of Dabigatran: The potential role of Multidrug and Toxin Extrusion (MATE) proteins. Shen H, Yao M, Sinz M, Marathe P, Rodrigues AD, Zhu M. PubMed
AAPS J. 2019;21:78. Guidance for Rifampin and Midazolam dosing protocols to study intestinal and hepatic Cytochrome P450 (CYP) 3A4 induction and de-induction. Kapetas AJ, Sorich MJ, Rodrigues AD, Rowland A. PubMed
J Pharmacol Exp Ther. 2019;370:72-83. Quantitative contribution of six major transporters to the hepatic uptake of drugs: "SLC-phenotyping" using primary human hepatocytes. Bi YA, Costales C, Mathialagan S, West M, Eatemadpour S, Lazzaro S, Tylaska L, Scialis R, Zhang H, Umland J, Kimoto E, Tess DA, Feng B, Tremaine LM, Varma MVS, Rodrigues AD. PubMed
Drug Metab Dispos. 2019;47:493-503. Mechanistic evaluation of the complex drug-drug interactions of Maraviroc: contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1. Kimoto E, Vourvahis M, Scialis RJ, Eng H, Rodrigues AD, Varma MVS. PubMed
J Clin Pharmacol. 2019;59:872-879. Use of Physiologically Based Pharmacokinetic Modeling to identify physiological and molecular characteristics driving variability in Axitinib exposure: A fresh approach to precision dosing in oncology. Sorich MJ, Mutlib F, van Dyk M, Hopkins AM, Polasek TM, Marshall JC, Rodrigues AD, Rowland A. PubMed
CPT Pharmacometrics Syst Pharmacol. 2018;7:739-747. PBPK Modeling of Coproporphyrin I as an endogenous biomarker for drug interactions involving inhibition of hepatic OATP1B1 and OATP1B3. Yoshikado T1, Toshimoto K, Maeda K, Kusuhara H, Kimoto E, Rodrigues AD, Chiba K, Sugiyama Y. PubMed
Clin Pharmacol Ther. 2018;104:916-932. Can Bile Salt Export Pump inhibition testing in drug discovery and development reduce liver injury risk? An International Transporter Consortium perspective. Kenna JG, Taskar KS, Battista C, Bourdet DL, Brouwer KLR, Brouwer KR, Dai D7, Funk C, Hafey MJ, Lai Y, Maher J, Pak YA, Pedersen JM, Polli JW, Rodrigues AD, Watkins PB, Yang K3 Yucha RW1; International Transporter Consortium. PubMed
Drug Metab Dispos. 2018;46:1581-1587. Physiologically relevant, humanized intestinal systems to study metabolism and transport of small molecule therapeutics: Mini-review. Sawant-Basak A, Rodrigues AD, Lech M, Doyonnas R, Kasaian M, Prasad B, Tsamandouras N. PubMed
Mol Pharm. 2018;15:3227-3235. Quantification of hepatic organic anion transport proteins OAT2 and OAT7 in human liver tissue and primary hepatocytes. Vildhede A, Kimoto E, Rodrigues AD, Varma MVS. PubMed
Drug Metab Dispos. 2018;46:1179-1189. Simultaneous assessment of transporter-mediated drug-drug interactions using a probe drug cocktail in Cynomolgus monkey. Kosa RE, Lazzaro S, Bi YA, Tierney B, Gates D, Modi S, Costales C, Rodrigues AD, Tremaine LM, Varma MV. PubMed
J Appl Toxicol. 2018;38:1336-1352. Species differences in bile acids II. Bile acid metabolism. Thakare R, Alamoudi JA, Gautam N, Rodrigues AD, Alnouti Y. PubMed
J Appl Toxicol. 2018;38:1323-1335. Species differences in bile acids I. Plasma and urine bile acid composition. Thakare R, Alamoudi JA, Gautam N, Rodrigues AD, Alnouti Y. PubMed
Bioanalysis. 2018;10:615-618. Endogenous probes for human liver organic anion-transporting polypeptides: the intersection of bioanalytical and ADME science. Rodrigues AD. PubMed
Bioanalysis. 2018;10:673-689. LC-MS/MS assay for N1-methylnicotinamide in humans, an endogenous probe for renal transporters.Luo L, Kay J, Zhang J, Holliman CL, Rodrigues AD, Dowty M, Banfield C, Ramanathan R. PubMed
Bioanalysis. 2018;10:645-657. A multiplex HRMS assay for quantifying selected human plasma bile acids as candidate OATP biomarkers. Rago B, Tierney B, Rodrigues AD, L Holliman C, Ramanathan R. PubMed
Bioanalysis. 2018;10:691-701. A fully automated and validated human plasma LC-MS/MS assay for endogenous OATP biomarkers coproporphyrin-I and coproporphyrin-III. King-Ahmad A, Clemens S, Ramanathan R, Zhang Y, Raha N, Zhang Y, Holliman C, Rodrigues AD, Li F. PubMed
Drug Metab Dispos. 2018;46:989-1000. Predicting human clearance of Organic Anion Transporting Polypeptide substrates using Cynomolgus monkey: In vitro-in vivo scaling of hepatic uptake clearance. De Bruyn T, Ufuk A, Cantrill C, Kosa RE, Bi YA, Niosi M, Modi S, Rodrigues AD, Tremaine LM, Varma MVS, Galetin A, Houston JB. PubMed
J Pharmacol Exp Ther. 2018;365:688-699. In vitro-in vivo extrapolation of OATP1B-mediated drug-drug interactions in Cynomolgus Monkey. Ufuk A, Kosa RE, Gao H, Bi YA, Modi S, Gates D, Rodrigues AD, Tremaine LM, Varma MVS, Houston JB, Galetin A. PubMed
Drug Metab Dispos. 2018;46:692-696. Comparison of proteomic quantification approaches for hepatic drug transporters: Multiplexed global quantitation correlates with targeted proteomic quantitation. Vildhede A, Nguyen C, Erickson BK, Kunz RC, Jones R, Kimoto E, Bourbonais F, Rodrigues AD, Varma MVS. PubMed
Mol Pharm. 2018;15:1284-1295. Role of hepatic Organic Anion Transporter 2 in the pharmacokinetics of R- and S-Warfarin: In vitro studies and mechanistic evaluation. Bi YA, Lin J, Mathialagan S, Tylaska L, Callegari E, Rodrigues AD, Varma MVS. PubMed
J Pharmacol Exp Ther. 2018;364:390-398. Organic Anion Transporter 2 mediates hepatic uptake of Tolbutamide, a CYP2C9 probe drug. Bi YA, Mathialagan S, Tylaska L, Fu M, Keefer J, Vildhede A, Costales C, Rodrigues AD, Varma MVS. PubMed
Bioanalysis. 2017;9:1787-1806. A highly selective and sensitive LC-MS/HRMS assay for quantifying coproporphyrins as organic anion-transporting peptide biomarkers. Ramanathan R, King-Ahmad AJ, Holliman CL, Rodrigues AD. PubMed
Xenobiotica. 2017;48:1037-1049. In vitro studies with two human Organic Anion Transporters: OAT2 and OAT7. Mathialagan S, Costales C, Tylaska L, Kimoto E, Vildhede A, Johnson J, Johnson N, Sarashina T, Hashizume K, Isringhausen CD, Vermeer LMM, Wolff AR, Rodrigues AD. PubMed
Clin Pharmacol Ther. 2017;103:434-448. Endogenous probes for drug transporters: balancing vision with reality. Rodrigues AD, Taskar KS, Kusuhara H, Sugiyama Y. PubMed
Chem Res Toxicol. 2017;30:1219-1229. Evaluating the role of Multidrug Resistance Protein 3 (MDR3) inhibition in predicting drug-induced liver injury using 125 pharmaceuticals. Aleo MD, Shah F, He K, Bonin PD, Rodrigues AD. PubMed
J Pharm Sci. 2017;106:2535-2541. Evaluation of renal transporter inhibition using creatinine as a substrate in vitro to assess the clinical risk of elevated serum creatinine. Mathialagan S, Rodrigues AD, Feng B. PubMed
AAPS J. 2017;19:787-796. Reliable rate measurements for active and passive hepatic uptake using plated human hepatocytes. Bi YA, Scialis RJ, Lazzaro S, Mathialagan S, Kimoto E, Keefer J, Zhang H, Vildhede AM, Costales C, Rodrigues AD, Tremaine LM, Varma MVS. PubMed
Clin Pharmacol Ther. 2017; 102:33-36. Extended Clearance Classification System (ECCS) informed approach for evaluating investigational drugs as substrates of drug transporters. Varma MV, El-Kattan AF, Feng B, Steyn SJ, Maurer TS, Scott DO, Rodrigues AD, Tremaine LM. PubMed
Drug Metab Dispos. 2017;45:228-236. Organic Anion Transporter 2: An Enigmatic Human Solute Carrier. Shen H, Lai Y, Rodrigues AD. PubMed
Chem Res Toxicol. 2016;29, 1778–1788 Inhibition of hepatobiliary transport activity by the antibacterial agent fusidic acid: insights into factors contributing to conjugated hyperbilirubinemia/cholestasis. Lapham K, Novak J, Marroquin LD, Swiss R, Qin S, Strock CJ, Scialis R, Aleo MD, Schroeter T, Eng H, Rodrigues AD, Kalgutkar AS. PubMed
Clin Pharmacol Ther. 2017;101:406-415. Transporter-mediated hepatic uptake plays an important role in the pharmacokinetics and drug-drug interactions of Montelukast. Varma MV, Kimoto E, Scialis R, Bi Y, Lin J, Eng H, Kalgutkar AS, El-Kattan AF, Rodrigues AD, Tremaine LM. PubMed
Drug Metab Dispos. 2016;44:320-8. Diclofenac and its acyl glucuronide: determination of in vivo exposure in human subjects and characterization as human drug transporter substrates in vitro. Zhang Y, Han YH, Putluru SP, Matta MK, Kole P, Mandlekar S, Furlong MT, Liu T, Iyer RA, Marathe P, Yang Z, Lai Y, Rodrigues AD. PubMed
Drug Metab Dispos. 2016;44:238-49. Cynomolgus monkey as a clinically relevant model to study transport involving renal organic cation transporters: in vitro and in vivo evaluation. Shen H, Liu T, Jiang H, Titsch C, Taylor K, Kandoussi H, Qiu X, Chen C, Sukrutharaj S, Kuit K, Mintier G, Krishnamurthy P, Fancher RM, Zeng J, Rodrigues AD, Marathe P, Lai Y. PubMed
Drug Metab Dispos. 2015;43:1108-18. Quantitative rationalization of Gemfibrozil drug interactions: consideration of transporters-enzyme interplay and the role of circulating metabolite Gemfibrozil 1-O-β-Glucuronide. Varma MV, Lin J, Bi YA, Kimoto E, Rodrigues AD. PubMed
J Pharmacol Exp Ther. 2015;353:380-91. Evaluation of rosuvastatin as an organic anion transporting polypeptide (OATP) probe substrate: in vitro transport and in vivo disposition in cynomolgus monkeys. Shen H, Su H, Liu T, Yao M, Mintier G, Li L, Fancher RM, Iyer R, Marathe P, Lai Y, Rodrigues AD. PubMed
Clin Pharmacol Ther. 2015;97:159-66. Organic anion transporting polypeptide-mediated transport of, and inhibition by, asunaprevir, an inhibitor of hepatitis C virus NS3 protease. Eley T, Han YH, Huang SP, He B, Li W, Bedford W, Stonier M, Gardiner D, Sims K, Rodrigues AD, Bertz RJ. PubMed
Drug Metab Dispos. 2014;42:566-74. Drug-induced perturbations of the bile acid pool, cholestasis, and hepatotoxicity: mechanistic considerations beyond the direct inhibition of the bile salt export pump. Rodrigues AD, Lai Y, Cvijic ME, Elkin LL, Zvyaga T, Soars MG. PubMed
J Biomol Screen. 2013;18:1072-83. Development of novel, 384-well high-throughput assay panels for human drug transporters: drug interaction and safety assessment in support of discovery research. Tang H, Shen DR, Han YH, Kong Y, Balimane P, Marino A, Gao M, Wu S, Xie D, Soars MG, O'Connell JC, Rodrigues AD, Zhang L, Cvijic ME. PubMed
Drug Metab Dispos. 2013;41:2095-103. Assessment of vandetanib as an inhibitor of various human renal transporters: inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance. Shen H, Yang Z, Zhao W, Zhang Y, Rodrigues AD. PubMed
Drug Metab Dispos. 2013;41:906-15. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats. Zhang D, Frost CE, He K, Rodrigues AD, Wang X, Wang L, Goosen TC, Humphreys WG. PubMed
J Pharmacol Exp Ther. 2013;344:673-85. Cynomolgus monkey as a potential model to assess drug interactions involving hepatic organic anion transporting polypeptides: in vitro, in vivo, and in vitro-to-in vivo extrapolation. Shen H, Yang Z, Mintier G, Han YH, Chen C, Balimane P, Jemal M, Zhao W, Zhang R, Kallipatti S, Selvam S, Sukrutharaj S, Krishnamurthy P, Marathe P, Rodrigues AD. PubMed
Xenobiotica. 2011;41:476-85. Effect of interferon-α2b on the expression of various drug-metabolizing enzymes and transporters in co-cultures of freshly prepared human primary hepatocytes. Chen C, Han YH, Yang Z, Rodrigues AD. PubMed
Drug Metab Dispos. 2010;38:1064-71. Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human kidney drug transporters. Han YH, Busler D, Hong Y, Tian Y, Chen C, Rodrigues AD. PubMed
Methods Mol Biol. 2010;596:385-403. Examination of CYP3A and P-glycoprotein-mediated drug-drug interactions using animal models. Marathe PH, Rodrigues AD. PubMed
Curr Drug Metab. 2006;7:687-704. In vivo animal models for investigating potential CYP3A- and Pgp-mediated drug-drug interactions. Marathe PH, Rodrigues AD. PubMed